

![]() |
|||||||||||||
|
| All | Since 2020 | |
| Citation | 6651 | 4087 |
| h-index | 26 | 21 |
| i10-index | 174 | 83 |
Search
News & Updation
FAP INHIBITORS: IN DIABETIC NEPHROPATHY?
Dr. Navneet Omprakash Soni*
ABSTRACT FAP inhibitor increases the endogenous level of FGF-21which may help in various Metabolic disease, Diabetes and Diabetic complication. Animal model have shown FGF-21 has protected renal damage in Diabetic animal model. However inhibition by FAP inhibitor and raised level of endogenous FGF-21,such raised endogenous FGF-21 have nephroprotective effect have not yet evaluated but FGF-21 mimetic drugs are in trial for Diabetes and metabolic disorder even FGF-21 MIMETICS are not evaluated for Diabetic nephropathy. Probable benefits of FAP inhibitors are highlighted based on evidence and study report. Keywords: FGF-21, CHD, FAP, FAP Inhibitor, Diabetic Nephropathy. [Download Article] [Download Certifiate] |
